GleamWall
中文EN

RNXT RenovoRx, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1574094 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-17.2%
TTM EPS YoY13.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin84.0%
Operating margin-489.0%
Net margin-469.0%
FCF margin-440.4%
EBITDA margin-416.6%

Returns

ROE-150.0%
ROA-110.1%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets25.4%
Debt / equity0.00x
Current ratio5.65x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.12M$43,000
Cost of revenue$327,000$0
Gross profit$796,000$43,000
R&D expense$6.27M$6.03M
SG&A expense$7.04M$4.99M
Operating income-$12.51M-$10.97M
Pretax income-$11.17M-$8.75M
Income tax$2,000—
Net income-$11.17M-$8.81M
EBITDA-$10.51M-$10.97M
EPS (basic)-0.32-0.40
EPS (diluted)-0.32-0.40
Weighted avg. shares (diluted)35.33M22.27M
Balance sheet
Cash & equivalents$7.02M$7.15M
Receivables$139,000$43,000
Inventory$189,000$0
Current assets$7.89M$7.83M
PP&E, net$12,000$12,000
Total assets$8.10M$8.12M
Current liabilities$1.96M$1.91M
Total liabilities$2.67M$3.64M
Shareholders' equity$5.42M$4.48M
Shares outstanding36.61M24.03M
Cash flow statement
Operating cash flow-$10.97M-$9.12M
Capital expenditure$2,000$12,000
Free cash flow-$10.97M-$9.14M
Investing cash flow-$2,000-$12,000
Financing cash flow$10.85M$15.12M
Depreciation & amortization$2.00M$0
Stock-based compensation$1.27M$1.17M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.